Jorveza® – the expected preparation for the treatment of eosinophilic esophagitis

Česká verze

Authors: Kajzrlíková Mikoviny I.
Authors place of work: Beskydské Gastrocentrum, Interní oddělení, Nemocnice ve Frýdku‑Místku, p. o.
Published in the journal: Gastroent Hepatol 2020; 74(4): 357-359
Category: Lékový profil
doi: https://doi.org/10.14735/amgh2020357

Zdroje

1. Lucendo AJ, Molina-Infante J, Arias A et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J 2017; 5 (3): 335–358. doi: 10.1177/2050640616689525.

2. Menclová A, Hojný M, Dulavová M et al. Nové možnosti léčby eozinofilní ezofagitidy pomocí magistraliter připravovaného léčiva. Prakt Lékáren 2016; 12 (1): 26–28. doi: 10.36290/lek.2016.006.

3. Dellon ES, Woosley JT, Arrington A et al. Efficacy of budesonide vs fluticasone for initial treatment of eosinophilic esophagitis in a randomized controlled trial. Gastroenterology 2019; 157 (1): 65–73.e65. doi: 10.1053/j.gastro.2019. 03.014.

4. Schlag C, Miehlke S, Lucendo A et al. Efficacy of budesonide orodispersible tablets for induction of remission in patients with active eosinophilic esophagitis: results from the 6-weeks open-label treatment phase of EOS-2 trial. Gastroenterology 2019; 156 (6): S-715. doi: 10.1016/S0016-5085 (19) 38723-2.

5. Lucendo AJ, Miehlke S, Schlag C et al. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial. Gastroenterology 2019; 157 (1): 74–86.e15. Gastroenterology 2019; 157 : 74–86 e15.

6. Lucendo A, Miehlke S, Vieth M et al. Budesonide orodispersible tablets are highly effective to maintain clinico-histological remission in adult patients with eosinophilic esophagitis: results from the 48 weeks, double-blind, placebo-controlled, Pivotal EOS-2 trial. Gastroenterology 2019; 156 (6): S-1509. doi: 10.1016/S0016-5085 (19) 40852-4.

7. Miehlke S, Hruz P, Vieth M et al. A randomised, double blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. Gut 2016; 65 (3): 390–399. doi: 10.1136/gutjnl-2014-308815.